IP Library Granted Patent US 10,500,199
Granted Patent B2
US 10,500,199 · App. 15/829,801 · Granted Dec 10, 2019

Nutritional supplement for increasing cognitive functions

Inventor: Bassam Damaj (San Diego, CA)
Assignee: Innovus Pharmaceuticals, Inc.
A61K31/4525A23L33/175A61K31/198A61P25/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,500,199
App. No.
15/829,801
Granted
Dec 10, 2019
Kind
B2
Abstract

The invention provides compositions and methods that are effective to improve NO production in vivo and/or to increase NO levels in blood. Such compositions and methods are useful to increase oxygenation of the brain and to improve cognitive function.

Claims (25)

1. A unit dosage form suitable for oral administration to a human comprising:

L-citrulline 500 mg±20 mg;

L-arginine 250 mg±20 mg; and

at least about 5 mg piperine.

2. The unit dosage form of claim 1 that comprises at least about 5.0 mg piperine.

3. The unit dosage form of claim 1 that comprises at least about 5.3 mg piperine.

4. The unit dosage form of claim 1 that comprises at least about 5.5 mg piperine.

5. The unit dosage form of claim 1 that further comprises microcrystalline cellulose, silicon dioxide, and magnesium stearate.

6. The unit dosage form of claim 1 that comprises at least about 480 mg of L-citrulline.

7. The unit dosage form of claim 1 that comprises at least about 490 mg of L-citrulline.

8. The unit dosage form of claim 1 that comprises at least about 500 mg of L-citrulline.

9. The unit dosage form of claim 1 that comprises at least about 230 mg of L-arginine.

10. The unit dosage form of claim 1 that comprises at least about 240 mg of L-arginine.

11. The unit dosage form of claim 1 that comprises at least about 250 mg of L-arginine.

12. The unit dosage form of claim 1 that comprises:

about 500 mg of L-citrulline;

about 250 mg of L-arginine; and

about 5 mg of (2E,4E)-5-(1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)penta-2,4-dien-1-one.

13. The unit dosage form of claim 1 wherein the piperine is synthetically produced piperine.

14. The unit dosage form of claim 1 wherein the piperine is an extract from the fruit of Piper.

15. The unit dosage form of claim 12 that further comprises microcrystalline cellulose, silicon dioxide, and magnesium sterate.

16. The unit dosage form of claim 1 that is formulated as a capsule, powder, or liquid.

17. A method to increase NO levels in the blood of a mammal comprising administering a unit dosage form of claim 1 to the mammal.

18. A method to increase oxygenation of the brain in a mammal comprising administering a unit dosage form of claim 1 to the mammal.

19. A method to improve cognitive function in a mammal comprising administering a unit dosage form of claim 1 to the mammal.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jun 14, 2024
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
To: INNOVUS PHARMACEUTICALS, INC.
Reel/Frame 067728/0206 →
PARTIAL RELEASE OF SECURITY INTEREST IN PATENTS Recorded Oct 16, 2023
From: ECLIPSE BUSINESS CAPITAL LLC (F/K/A ENCINA BUSINESS CREDIT, LLC), AS AGENT
To: INNOVUS PHARMACEUTICALS, INC.; SEMPRAE LABORATORIES, INC.; AYTU BIOPHARMA, INC.; NOVALERE, INC.
Reel/Frame 065241/0560 →
SECURITY INTEREST Recorded Feb 10, 2022
From: INNOVUS PHARMACEUTICALS, INC.
To: AVENUE VENTURE OPPORTUNITIES FUND II, L.P.
Reel/Frame 058976/0706 →
SECURITY INTEREST Recorded Jan 27, 2022
From: INNOVUS PHARMACEUTICALS, INC.; SEMPRAE LABORATORIES, INC.
To: ECLIPSE BUSINESS CAPITAL LLC (F/K/A ENCINA BUSINESS CREDIT, LLC), AS AGENT
Reel/Frame 058789/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2018
From: DAMAJ, BASSAM
To: INNOVUS PHARMACEUTICALS, INC.
Reel/Frame 046295/0899 →